


Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

APR 14 2004

(Use several sheets if necessary)

Docket Number 549062000100

Application Number 10/722,849

Applicant

Jing MA

Filing Date November 26, 2003

Group Art Unit: 1614

Mailing Date April 12, 2004

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
/BD/	1.	<del>12/01/1999</del>	<del>09/451,353</del>	<del>Ma</del>			
	2.	08/01/2002	2002/0102278	Guo			
	3.	07/28/1987	4,683,195	Mullis et al.			
	4.	07/28/1987	4,683,202	Mullis			
	5.	03/22/1988	4,732,864	Tolman			
	6.	06/28/1988	4,754,065	Levenson et al.			
	7.	01/24/1989	4,800,159	Mullis et al.			
	8.	03/28/1989	4,816,567	Cabilly et al.			
	9.	12/04/1990	4,975,278	Senter et al.			
	10.	09/03/1996	5,552,391	Coutts et al.			
	11.	10/15/1996	5,565,332	Hoogenboom et al.			
	12.	12/03/1996	5,580,717	Dower et al.			
	13.	03/31/1998	5,733,743	Johnson et al.			
	14.	09/15/1998	5,807,715	Morrison et al.			
	15.	02/02/1999	5,866,692	Shitara et al.			
	16.	12/07/1999	5,997,867	Waldmann et al.			
	17.	04/25/2000	6,054,297	Carter et al.			
	18.	01/30/2001	6,180,377	Morgan et al.			
	19.	04/03/2001	6,210,671	Co			
	20.	07/24/2001	6,265,150	Terstappen et al.			
	21.	12/18/2001	6,331,415	Cabilly et al.			
	22.	02/26/2002	6,350,861	Co et al			
	23.	08/27/2002	6,441,163	Chari et al.			

## FOREIGN PATENT DOCUMENTS

Examiner	Ref.	Date	Document No.	Country	Class	Subclass	Translation
----------	------	------	--------------	---------	-------	----------	-------------

EXAMINER:

/Brad Duffy/

DATE CONSIDERED:

04/26/2007

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

pa- 855638

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>				Docket Number 549062000100		Application Number 10/722,849	
				Applicant			
				Jing MA			
				Filing Date November 26, 2003		Group Art Unit: 1614	
				Mailing Date April 12, 2004			

Initials	No.	Date	Patent No.	Country	Priority	Priority	Priority	YES	NO
/BD/	24.	12/23/1992	EP 519,596	Europe					
	25.	04/30/1981	WO 81/01145	WIPO					
	26.	10/06/1988	WO 88/07378	WIPO					
	27.	04/01/1993	WO 93/06213	WIPO					
	28.	04/19/2001	WO 01/27160	WIPO					

OTHER DOCUMENTS		
Examiner Initials	Ref. No.	Title
/BD/	29.	Al-Lazikani, B. et al. (1997). "Standard Conformations fo the Canonical Structures of Immunoglobulins," <i>J. Molec. Biol.</i> 273(4):927-948.
	30.	Brown, B. A. et al. (1987). "Tumor-Specific Genetically Engineered Murine/Human Chimeric Monoclonal Antibody," <i>Cancer Res.</i> 47:3577-3583.
	31.	Chothia, C. et al. (1989). "Conformations of Immunoglobulin Hypervariable Regions," <i>Nature</i> 342(6252):877-883.
	32.	Clackson, T. et al. (1991). "Making Antibody Fragments Using Phage Display Libraries," <i>Nature</i> 352(6336):624-628.
	33.	Dai, J. et al. (2003). "Monoclonal Antibody SM5-1 Can Inhibit Tumor Cells' Growth and Induce Caspase-10 Related Apoptosis," <i>Clinical Cancer Research</i> 9(C13):6206S-6207S.
	34.	Daugherty, B.L. et al. (1991). "Polymerase Chain Reaction Facilities the Cloning, CDR-Grafting, and Rapid Expression of a Murine Monoclonal Antibody Directed Against the CD18 Component of Leukocyte Integrins," <i>Nucl. Acids Res.</i> 19(9):2471-2476.
	35.	Dayoff, M. O. et al. (1978). "A Model of Evolutionary Change in Proteins," Chapter 22 <i>In Atlas of Protein Sequence and Structure</i> . The National Biomedical Research Foundation 5(3):345-352.
	36.	Griffiths, A.D. et al. (1993). "Human Anti-Self Antibodies with High Specificity From Phage Display Libraries," <i>EMBO J.</i> 12(2):725-734.
	37.	Griffiths, A.D. et al. (1994). "Isolation of High Affinity Human Antibodies Directly From Large Synthetic Repertoires," <i>EMBO J.</i> 13(14):3245-3260.
	38.	Guo, Y. et al. (1994). "Inhibition of Human Melanoma Growth and Metastasis <i>In Vivo</i> by Anti-CD44 Monoclonal Antibody," <i>Cancer Res.</i> 54(6):1561-1565.
	39.	Haidaris, C.G. et al. (2001). "Recombinant Human Antibody Single Chain Variable Fragments Reactive with <i>Candida Albicans</i> Surface Antigens," <i>J. Immunol. Methods</i> 257(1-2):185-202.
	40.	Hein, J. (1990). "Unified Approach to Alignment and Phylogenes," <i>Methods in Enzymology</i> 183:626-644.

EXAMINER: /Brad Duffy/	DATE CONSIDERED: 04/26/2007
------------------------	-----------------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>		Docket Number 549062000100      Application Number 10/722,849  Applicant <div style="text-align: center;">Jing MA</div> Filing Date November 26, 2003      Group Art Unit: 1614  Mailing Date April 12, 2004	
/BD/	41.	Higgins, D.G. et al. (1989). "Fast and Sensitive Multiple Sequence Alignments on a Microcomputer," <i>CABIOS Communications</i> 5(2):151-153.	
↓	42.	Hirt, B. (1967). "Selective Extraction of Polyoma DNA from Infected Mouse Cell Cultures," <i>J. Mol. Biol.</i> 26:365-369.	
↓	43.	Hoogenboom, H. R. et al. (1992). "By-Passing Immunisation Human Antibodies from Synthetic Repertoires of Germline V <sub>H</sub> Gene Segments Rearranged <i>In Vitro</i> ," <i>J. Mol. Biol.</i> 227:381-388.	
↓	44.	Irie, R.F. et al. (1986). "Regression of Cutaneous Metastatic Melanoma by Intralesional Injection with Human Monoclonal Antibody to Ganglioside GD2," <i>PNAS USA</i> 83(22):8694-8698.	
↓	45.	Johnson, K. D. et al. (1993). "Human Antibody Engineering," <i>Current Opinion in Structural Biology</i> 3(4):564-571.	
↓	46.	Jones, P.T. et al. (1986). "Replacing the Complementarity-Determining Regions In A Human Antibody with Those From a Mouse," <i>Nature</i> 321:522-525.	
↓	47.	Karlsson, et al. (1991). "Kinetic Analysis of Monoclonal Antigen-Interactions With A New Biosensor Based Analytical System," <i>J. Immunol. Methods</i> 145:229-240.	
↓	48.	Kindblom, L-G. et al. (1984). "S-100 Protein in Melanocytic Tumors," <i>Acta. Pathol. Microbial Immunol. Scand</i> 92:219-230.	
↓	49.	Köhler, G. et al. (1975). "Continuous Cultures on Fused Cells Secreting Antibody of Predefined Specificity," <i>Nature</i> 256:495-497.	
↓	50.	Lobuglio, A.F. et al. (1989). "Mouse/Human Chimeric Monoclonal Antibody in Man: Kinetics and Immune Response," <i>PNAS USA</i> 86:4220-4224.	
↓	51.	Mahato, E.I. et al. (1997). "Cationic Lipid-Based Gene Delivery Systems: Pharmaceutical Perspectives," <i>Pharm. Res.</i> 14(7):853-859.	
↓	52.	Marken, J.S. et al. (1992). "Cloning and Expression of the Tumor-Associated Antigen L6," <i>PNAS USA</i> 89:3503-3507.	
↓	53.	Marks, J.D. et al. (1991). "By-Passing Immunization Human Antibodies From V-Gene Libraries Displayed on Phage," <i>J. Mol. Biol.</i> 222(3):581-597.	
↓	54.	Marks, J.D. et al. (1992). "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling," <i>BioTechnol.</i> 10(7):779-783.	
↓	55.	McCafferty, J. et al. (1990). "Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains," <i>Nature</i> 348(6301):552-554.	
↓	56.	Myers, E.W. et al. (1988). "Optimal Alignments in Linear Space," <i>CABIOS</i> 4(1):11-17.	
↓	57.	Nakajima, T. et al. (1982). "Immunohistochemical Demonstration of S100 Protein in Malignant Melanoma and Pigmented Nevus, and its Diagnostic Application," <i>Cancer</i> 50:912-918.	
↓	58.	Nissim, A. et al. (1994). "Antibody Fragments From 'Single Pot' Phage Display Library As Immunochemical Reagents," <i>EMBO J.</i> 13:692-698.	
EXAMINER:		DATE CONSIDERED:	
/Brad Duffy/		04/26/2007	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/ 08 (2-92) pa- 855638			
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE			

<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>		Docket Number 549062000100  Applicant <div style="text-align: center;">Jing MA</div>  Filing Date November 26, 2003  Mailing Date April 12, 2004	Application Number 10/722,849  Group Art Unit: 1614
/BD/	59.	Ordóñez, N.G. et al. (1988). "Comparison of HMB-45 Monoclonal Antibody and S-100 Protein in the Immunohistochemical Diagnosis of Melanoma," <i>Am. J. Clin. Pathol.</i> 90:385-390.	
↓	60.	Riechmann, L. et al. (1988). "Reshaping Human Antibodies For Therapy," <i>Nature</i> 332(6162):323-327.	
↓	61.	Robinson, E.D. (1971). "Comparison of Labeled Trees With Valency Three," <i>J. Comb. Theor.</i> 11:105-119.	
↓	62.	Saitou, N. et al. (1987). "The Neighbor-Joining Method: A New Method for Reconstructing Phylogenetic Trees," <i>Mol. Biol. Evol.</i> 4(4):406-425.	
↓	63.	Shaw, D.R. et al. (1987). "Characterization of a Mouse/Human Chimeric Monoclonal Antibody (17-1A) to a Colon Cancer Tumor-Associated Antigen," <i>J. Immuno.</i> 138(12):4534-4538.	
↓	64.	Smoller, B.R. et al. (1989). "HMB-45 Recognizes Stimulated Melanocytes," <i>J. Cutan. Pathol.</i> 16:49-53.	
↓	65.	Smoller, B.R. et al. (1989). "HMB-45 Staining of Dysplastic Nevi: Support for a Spectrum of Progression Toward Melanoma," <i>Am J. Surg Pathol.</i> 13(8):680-684.	
↓	66.	Smoller, B.R. (1994). "Immunohistochemistry in the Diagnosis of Melanocytic Neoplasms," <i>Pathology: State of the Art Reviews</i> 2(2):371-383.	
↓	67.	Verhoeven, M. et al. (1988). "Reshaping Human Antibodies: Grafting An Antilysozyme Activity," <i>Science</i> 239(4835):1534-1536.	
↓	68.	Waterhouse, P. et al (1993). "Combinatorial Infection and <i>In Vivo</i> Recombination: A Strategy for Making Large Phage Antibody Repertoires," <i>Nucl. Acids Res.</i> 21(9):2265-2266.	
↓	69.	Wick, M.R. et al. (1988). "Recognition of Malignant Melanoma By Monoclonal Antibody HMB-45. An Immunohistochemical Study of 200 Paraffin-Embedded Cutaneous Tumors," <i>J. Cutan Pathol.</i> 15(4):201-207.	
↓	70.	Wilber, W.J. et al. (1983). "Rapid Similarity Searches of Nucleic Acid and Protein Data Banks," <i>PNAS USA</i> 80:726-730.	
↓	71.	Winter, G. et al. (1991). "Man-Made Antibodies," <i>Nature</i> 349(6307):293-299.	
↓	72.	Winter, G. et al. (1994). "Making Antibodies By Phage Display Technology," <i>Annu. Rev. Immunol.</i> 12:433-455.	
↓	73.	Yang, L-J. et al. (2002). "Preparation of Monoclonal Antibody Against Apoptosis-Associated Antigens of Hepatoma Cells by Subtractive Immunization," <i>World J. Gastroenterol.</i> 8(5):808-814.	
EXAMINER:		DATE CONSIDERED:	
/Brad Duffy/		04/26/2007	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

JUL 14 2005

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/722,849
Filing Date	11/26/2003
First Named Inventor	Jing Ma
Group Art Unit	1643
Examiner Name	Unknown
Attorney Docket Number	047630-0201

Sheet 1 of 1

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
/BD/	A1	5554512		Lyman et al.	09-10-1996	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/BD/	A2	Van Spriel et al., "Immunotherapeutic perspective for bispecific antibodies." Immunology Today, 21(8): 391-397, 2000.	
/BD/	A3	International Search Report for international application No. PCT/US2004/47765.	

 Examiner  
 Signature

/Brad Duffy/

 Date  
 Considered

04/26/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: April 27, 2006 (use as many sheets as necessary)		<b>Complete if Known</b>	
Application Number		10/722,849	
Filing Date		11/26/2003	
First Named Inventor		MA	
Group Art Unit		1614	
Examiner Name		Unknown	
Attorney Docket Number		047630-0201	

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
/BD/	B1	6,214,318		Benz et al.	04/2001	
	B2	RE 32,417		Burchiel et al.	05/1987	
	B3	4,036,945		Haber	07/1977	
	B4	4,311,688		Burchiel et al.	01/1982	
	B5	4,472,371		Burchiel et al.	09/1984	
	B6	4,478,815		Burchiel et al.	10/1984	
	B7	4,478,818		Shell et al.	10/1984	
	B8	5,223,409		Ladner et al.	06/1993	
	B9	5,317,091		Subramanian	05/1994	
	B10	5,475,096		Gold et al.	12/1995	
	B11	5,530,101		Queen et al.	06/1996	
	B12	5,595,877		Gold et al.	01/1997	
	B13	5,660,985		Pieken, et al.	08/1997	
	B14	5,693,762		Queen et al.	12/1997	

## U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document		Name of Patentee or Applicant of Cited Document	Filing Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number	Kind Code <sup>2</sup> (if known)			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
/BD/	B15		WO 97/47271			12/1997		
	B16		WO 98/04282			02/1998		
	B17		WO 98/16238			04/1998		
	B18		WO 98/24884			06/1988		

Examiner Signature	/Brad Duffy/	Date Considered	04/26/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: April 27, 2006  (use as many sheets as necessary)		Application Number	10/722,849
		Filing Date	11/26/2003
		First Named Inventor	MA
		Group Art Unit	1614
		Examiner Name	Unknown
Sheet	2	of	8
		Attorney Docket Number	047630-0201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/BD/	B19	Aamdal et al. "Immunomagnetic Detection of Melanoma Cells in bone Marrow and Blood" Melanoma Research 7 (Suppl. 1):S35 (1997)	
	B20	Adema et al. "Molecular Characterization of the Melanocyte Lineage-Specific Antigen gp100" J. Invest. Dermatol. 103:269-276 (1994)	
	B21	Argenyi et al. "S100 Protein-negative Malignant melanoma: Fact or Fiction? A light-Microscopic and Immuno-Histochemical Study" Am. J. Dermatopathol. 16:233-240 (1994)	
	B22	Brooks et al. J. "Subtractive Immunization Yields Monoclonal Antibodies that specifically Inhibit Metastasis" Cell Biol. 122(6):1351-1359 (1993)	
	B23	Chen et al. "A Melanoma Associated Fibronectin Variant Characterized by Monoclonal Antibody SM5-1" Journal of Molecular Medicine 76: page B11 (1998)	
	B24	Cochran et al. "Detection of S100 Protein as an Aid to the Identification of Melanocytic Tumors" Int. J. Cancer 30: 295-297 (1982)	
	B25	Cohen et al. "Production and Characterisation of an Antimelanoma Monoclonal Antibody KBA.62 Using a New Melanoma Cell Line Reactive on paraffin Wax Embedded Sections" J.Clin. Pathol. 48:826-831 (1995)	
	B26	Colombiari et al. "Distribution of Melanoma Specific Antibody (Hmb-45) in Benign and Malignant Melanocytic Tumors" Virchows Archiv. A Pathol Anat. 413:17-24 (1988)	
	B27	Drier et al. "S100 Protein Immunoreactivity in Poorly Differentiated Carcinomas. Immuno-Histochemical Comparison with Malignant Melanoma" Arch. Pathol. Lab. Med. 111:447-452 (1987)	
	B28	Emery and Harris. "Strategies for Humanizing Antibodies" Chapter 6 In <u>Antibody Engineering 2<sup>nd</sup></u> Ed. Pp. 159-183 (1995)	
	B29	Esclamado et al. "Unique Proteins Defined by Monoclonal Antibodies Specific for Human Melanoma. Some Potential Clinical Applications" Am. J. Surg. 152:376-385 (1986)	
	B30	Frye et al. "Detection of Amplified Oncogenes by Differential Polymerase Chain Reaction" Oncogene 4:1153-1157 (1987)	

Examiner Signature	/Brad Duffy/	Date Considered	04/26/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: April 27, 2006  (use as many sheets as necessary)		Application Number	10/722,849
		Filing Date	11/26/2003
		First Named Inventor	MA
		Group Art Unit	1614
		Examiner Name	Unknown
Sheet	3	of	8
		Attorney Docket Number	047630-0201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/BD/	B31	Gatter et al. "An Immunocytochemical Study of Malignant melanoma and its Differential Diagnosis from Other Malignant Tumors" J. Clin. Pathol. 38:1353-1357 (1985)	
	B32	Giomo. "A Comparison of Two Immunoperoxidase Staining Methods Based on the Avidin-Biotin Interaction" Diag. Immunol. 2:161-166 (1984)	
	B33	Gown et al. "Monoclonal Antibodies Specific for Melanocytic Tumors Distinguished Subpopulations of Melanocytes" Am. J. Pathol. 123:195-203 (1986)	
	B34	Guo et al. "Inhibition of Human melanoma Growth and Metastasis In Vivo by Anti-CD44 Monoclonal Antibody" Cancer Res. 54:1561-1565 (1994)	
	B35	Hachisuka et al. "Immuno-Histochemical Study of S100 Protein and Neuron Specific Enolase (NSE) in Melanocytes and the Related Tumors" Acta Histochem. 80:215-223 (1986)	
	B36	Hannum et al. "Ligand for FLT/3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs" Letters to Nature 368: 643-648 (1994)	
	B37	Harlow and Lane. Chapter 12 In <u>Antibodies-A Laboratory Manual</u> cold Spring Harbor Laboratory pp. 471-510 (1988)	

Examiner Signature	/Brad Duffy/	Date Considered	04/26/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: April 27, 2006  (use as many sheets as necessary)		Application Number	10/722,849
		Filing Date	11/26/2003
		First Named Inventor	MA
		Group Art Unit	1614
		Examiner Name	Unknown
Sheet	4	of	8
		Attorney Docket Number	047630-0201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/BD/	B38	Harlow and Lane. Chapter 14 In <u>Antibodies-A Laboratory Manual</u> cold Spring Harbor Laboratory pp. 553-612 (1988)	
	B39	Harlow and Lane. "Immunoaffinity Purification" Chapter 13 In <u>Antibodies-A Laboratory Manual</u> Cold Spring Harbor Laboratory pp. 511-552 (1988)	
	B40	Herrera and Hancock. "Specificity of Antibody HMB-45" Arch. Pathol. La. Med. 116:900-901 (1992)	
	B41	Hung et al. "Enhancement of DNA Vaccine Potency by Linkage of Antigen Gene to a Gene Encoding the Extracellular Domain of Fms-like Tyrosine Kinase 3-Ligand" Cancer Research 61: 1080-1088 (2001)	
	B42	<del>International Search Report for PCT Application No. PCT/US2004/040870</del>	
	B43	Köhler et al. "Derivation of Specific Antibody Producing Tissue Culture and Tumor Lines by Cell Fusion" Eur. J. Immunol. 6:511-519 (1976)	
	B44	Mackie et al. "Use of NK1 C3 Monoclonal Antibody in the Assessment of Benign and Malignant Melanocytic Lesions" J. Clin. Pathol. 37:367-372 (1984)	

Examiner Signature	/Brad Duffy/	Date Considered	04/26/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: April 27, 2006  (use as many sheets as necessary)		Application Number	10/722,849
		Filing Date	11/26/2003
		First Named Inventor	MA
		Group Art Unit	1614
		Examiner Name	Unknown
Sheet	5	of	8
		Attorney Docket Number	047630-0201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/BD/	B45	McCarthy et al. "Localization and Chemical Synthesis of Fibronectin Peptides with Melanoma Adhesion and Heparin Binding Activities" Biochemistry 27:1380-1388 (1988).	
	B46	Mottolese et al. "Immunocytochemical diagnosis of Amelanotic Metastatic Melanoma Using Monoclonal Antibodies HMB-45 and Epi-3" Melanoma Res. 4:53-58 (1994)	
	B47	Palazo and Duray. "Typical, Dysplastic, Congenital, and Spitz nevi: A Comparative Immuno-Histochemical Study" Hum. Pathol. 20:341-346 (1989)	
	B48	Reinke et al. "Differential Expression of MART-1, Tyrosinase, and SM5-1 in Primary and Metastatic Melanoma" Am. J. Dermatopathol. 27: 401-406 (2005)	
	B49	Rothman et al. "Structure and Expression of Germ Line Immunoglobulin Heavy-Chain $\epsilon$ Transcripts: Interleukin-4 Plus Lipopolysaccharide-Directed Switching to C $\epsilon$ " Molecular and Cellular Biology 10(4):1672-1679 (1990)	
	B50	Sekiguchi et al. Seikagaku, 1989,61, pp. 89-93 (abstract)	
	B51	Serafini et al. "Technetium-99m Labeled Monoclonal Antibodies in the Detection of Metastatic Melanoma" Clinical Nuclear Medicine 14(8):580-587 (1989)	

Examiner Signature	/Brad Duffy/	Date Considered	04/26/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: April 27, 2006  (use as many sheets as necessary)		Application Number	10/722,849
		Filing Date	11/26/2003
		First Named Inventor	MA
		Group Art Unit	1614
		Examiner Name	Unknown
Sheet	6	of	8
		Attorney Docket Number	047630-0201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/BD/	B52	Shi et al. "Antigen Retrieval in Formalin-Fixed, Paraffin-Embedded Tissues: An Enhancement Method for Immuno-Histochemical Staining Based on Microwave Oven Heating of Tissue Sections" J. Histochem Cytochem. 39:741-748 (1991)	
	B53	Smith et al. "The Human Homologue of Rat NG2, a Chondroitin Sulfate Proteoglycan, Is Not Expressed on the Cell Surface of Normal Hematopoietic Cells But Is Expressed by Acute Myeloid Leukemia Blasts From Poor-Prognosis Patients with Abnormalities of Chromosome Band 11q23" The American Society of Hematology, Blood, 87(3):1123-1133 (1996)	
	B54	Springall et al. "The Value of S100 Immunostaining as a Diagnostic Tool in Human Malignant Melanomas. A Comparative Study Using S100 and Neuron-Specific Enolase Antibodies" Virchows Arch. Pathol. Anat. Histopathol. 400:331-343 (1983)	
	B55	Stefansson et al. "Distribution of S100 Protein Outside the Central Nervous System" Brain Res. 234:309-317 (1982)	
	B56	Stefansson et al. "S100 Protein in Human Chondrocytes" nature 295:63-64 (1982)	
	B57	Sun et al. "Antibody HMB-45 Identifies the Cells of Blue Nevii. An Immuno-Histochemical Study on Paraffin Sections" Am. J. Surg. Pathol. 14:748-751 (1990)	
	B58	Swerdlow et al. "Risks of Second Primary malignancy in Patients with Cutaneous and Ocular Melanoma in Denmark, 1943-1989" Int. J. Cancer 61:773-779 (1995)	

Examiner Signature	/Brad Duffy/	Date Considered	04/26/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: April 27, 2006  (use as many sheets as necessary)		Application Number	10/722,849
		Filing Date	11/26/2003
		First Named Inventor	MA
		Group Art Unit	1614
		Examiner Name	Unknown
Sheet	7	of	8
		Attorney Docket Number	047630-0201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/BD/	B59	Tabuchi et al. "A S100 Protein in Human Glial tumors. Qualitative and quantitative Studies" Aca Neurochir. Wien 65:239-251 (1982)	
	B60	Trefzer et al. "SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions" Arch. Dermatol. Res. 292:583-589 (2000)	
	B61	Trefzer et al. "SM5-1: A New Monoclonal Antibody Which is Highly Sensitive and Specific for Melanocytic Tumors" Journal of Dermatological Science 16 (Suppl. 1):S110 (1998)	
	B62	Trefzer et al. "The monoclonal antibody SM5-1 recognizes a fibronectin variant which is widely expressed in melanoma" BMC Cancer 6(8):1-12 (2006)	
	B63	Vanstapel et al. "New Sites of Human S100 Immunoreactivity Detected with Monoclonal Antibodies" Am. J. Clin. Pathol. 85:160-168 (1986)	
	B64	Vennegoor et al. "Biochemical Characterization and Cellular Localization of a Formalin-Resistant Melanoma-Associated Antigen Reacting with Monoclonal Antibody NK1/C-3" Int. J. Cancer 35:287-295 (1985)	
	B65	Williams et al "Subtractive Immunization Techniques for the Production of Monoclonal Antibodies to Rare Antigens" Biotechniques 12:842-847 (1992)	

Examiner Signature	/Brad Duffy/	Date Considered	04/26/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: April 27, 2006  (use as many sheets as necessary)		Application Number	10/722,849
		Filing Date	11/26/2003
		First Named Inventor	MA
		Group Art Unit	1614
		Examiner Name	Unknown
Sheet	8	of	8
		Attorney Docket Number	047630-0201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/BD/	B66	Wilson et al. "Sulfation and Molecular Weight of Fibronectin Shed by Human Melanoma Cells" Biochem Biophys Research Commun. 101:1047-1051 (1981)	
↓	B67	Wu et al. "Induction of Potent TRAIL-Mediated Tumoricidal Activity by hFLEX/Furin/TRAIL Recombinant DNA Construct" Molecular Therapy 9 (5):674-681 (2004)	
	B68	Wu et al. "Regression of Human Mammary Adenocarcinoma by Systemic Administration of a Recombinant Gene Encoding the hFlex-TRAIL Fusion Protein" Molecular Therapy 3:368-374 (2001)	

Examiner Signature	/Brad Duffy/	Date Considered	04/26/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.